Gyre Therapeutics, Inc.
GYRE
$8.68
-$2.53-22.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -13.01% | -6.78% | -8.49% | -0.29% | 8.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.01% | -6.78% | -8.49% | -0.29% | 8.89% |
| Cost of Revenue | -15.39% | -16.22% | -16.64% | -15.59% | -9.47% |
| Gross Profit | -12.91% | -6.38% | -8.14% | 0.42% | 9.79% |
| SG&A Expenses | -4.89% | -2.90% | 8.71% | -4.81% | 4.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.11% | -5.00% | 3.15% | -9.89% | -0.88% |
| Operating Income | -49.41% | -15.53% | -54.92% | 108.84% | 99.64% |
| Income Before Tax | 121.73% | 130.17% | -451.03% | -804.19% | -788.76% |
| Income Tax Expenses | -59.20% | -37.52% | -36.43% | 23.08% | 49.45% |
| Earnings from Continuing Operations | 114.66% | 120.94% | -742.29% | -2,583.23% | -1,978.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 43.60% | 22.00% | 38.62% | -18.20% | -97.82% |
| Net Income | 108.27% | 113.00% | -2,033.69% | -3,059.62% | -33,680.46% |
| EBIT | -49.41% | -15.53% | -54.92% | 108.84% | 99.64% |
| EBITDA | -44.52% | -12.40% | -50.98% | 98.12% | 91.19% |
| EPS Basic | 106.98% | 111.36% | -1,827.29% | -12,447.42% | -6,136.60% |
| Normalized Basic EPS | 213.61% | 783.44% | -130.89% | -7.55% | 2,222.22% |
| EPS Diluted | 101.54% | 103.65% | -3,080.89% | -25,990.00% | -5,061.60% |
| Normalized Diluted EPS | 593.00% | 320.84% | -172.83% | -133.99% | -47.06% |
| Average Basic Shares Outstanding | 21.38% | 29.26% | 28.55% | 59.84% | 122.53% |
| Average Diluted Shares Outstanding | 18.60% | 27.88% | 27.24% | 61.86% | 133.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |